The modulating effects of GLP-1 on platelet function might have protective roles on the cardiovascular system, thus suggesting that a reduced and/or impaired action of GLP-1 on platelets could be involved in the platelet hyperreactivity described in metabolic disorders such as diabetes [190,191] and dyslipidemia [192,193]. Here, GCG is linked to metabolic disease.